Skip Navigation
Skip to contents

IMKASID 2024

Abstract Submission

The IMKASID 2024 Organizing Committee cordially invites you to submit abstracts. All abstracts must be submitted online via the "Abstract Submission." Submitted abstracts will be reviewed by the Scientific Committee. Accepted abstracts will be presented as (1) Oral Presentation or (2) Poster Oral Presentation (E-Poster) or (3) Poster Exhibition (E-Poster) and will be published in the abstract book.
Please read the guidelines carefully before submitting your abstract.

Important Dates

  • Abstract Submission
    By December 5, 2023 Extended to
    January 5, 2024
    D--167
  • Notification of Abstract Acceptance
    January 23, 2024 D--149
  • Deadline for Presenters' Registration
    February 28, 2024 Extended to
    March 15, 2024
    D--113

Steps for Submission

  • STEP 01 Sign-up or Log in If you are already signed-up on this website, you can use the account for your abstract submission.
  • STEP 02 Submit Your Abstract Fill out author and abstract information and click "Save and Next" button.
  • STEP 03 Confirmation Letter After your abstract submission, a confirmation letter will be sent to you via
    E-mail.
  • STEP 04 My Page To review or modify your submitted abstracts, visit
    "MY PAGE" until the submission deadline.
  • STEP 05 Acceptance Notification An acceptance notification will be sent to you via E-mail.

Abstract Topic

# Topic 1 Topic 2 Topic 3
1 Inflammatory Bowel Disease Therapeutics Medical
2
Surgical
3 Complication
4
Prognosis
5 Others/Case
6 Diagnosis Epidemiology
7 Early Detection
8 Monitoring
9 Biomarker
10 Image
11 Artificial Intelligence
12 Others/Case
13 Basic/Translational Microbiome
14 FMT
15 Genetics
16 Immunology
17 Others/Case
18 Colorectal Neoplasia Therapeutics Endoscopy
19 Surgery
20 Complication
21 Prognosis
22 Others/Case
23 Diagnosis Epidemiology
24 Screening
25 Surveillance
26 Bowel Preparation
27 Image
28 Artificial Intelligence
29 Others/Case
30 Basic/Translational Microbiome
31 FMT
32 Genetics
33 Immunology
34 Others/Case
35 Small Bowel Disease & Nutrition Capsule Endoscopy
36 Enteroscopy
37 Image
38 Artificial Intelligence
39 Microbiome
40 Diet
41 Nutrition
42 Others/Case
43 General Topics Functional Disorder
44 Infectious Disease
45 Others/Case

Presentation Type

  • Oral Presentation
  • Poster Oral Presentation (E-Poster)
  • Poster Exhibition (E-Poster)

Submission Guidelines

Abstract Format
  • Title: Max 30 words
  • Body: Max 300 words
  • Up to 3 graphs/tables or images
  • All abstracts must be submitted online via the IMKASID 2024 website. Abstracts submitted by E-mail, fax or post will NOT be accepted.
  • Abstracts must be written in clear English submitted prior to Korea Standard Time 23:59, December 5 (Tue), 2023 January 5 (Fri), 2024.
  • The abstract should be objective and concise, including key information in its four section: Background/Aim, Methods, Results, Conclusions.
  • It is the responsibility of the authors to ensure that their text does not contain typos or grammatical errors.
  • Authors have the option of their preferred presentation type (oral presentation or Poster Exhibition (E-Poster)). However, the scientific committee will make the final decision on presentation type (oral presentation, Poster Oral Presentation (E-Poster) or Poster Exhibition (E-Poster)) after review of abstracts.
  • Abstracts submitted until December 5 (Tue), 2023 CANNOT be modified due to the abstract review.
    Abstracts submitted from December 6 (Wed), 2023 CAN be modified until the submission deadline on <MY PAGE>.
  • A confirmation of receipt of the abstract will be automatically sent to the submitter, the presenting author and corresponding author by E-mail upon their on-line submission. Therefore, please submit the right contact details. Otherwise, the presenter will not receive important information about his/her presentation.
  • The right to publish your abstract is granted to the IMKASID 2024 Organizing Committee.
  • The presenting author must register for the IMKASID 2024 during the period of pre-registration. If the presenting author does not complete registering with full payment by February 28, 2024 March 15, 2024 the abstract will be withdrawn.
  • If on-line submission is not possible, please contact the secretariat at info@imkasid.kr.

Structure

  • An acceptable structure of an abstract must consist of the following components:
    Background/Aim A statement of the hypothesis or research question.
    Methods An explanation of the study design and experimental methods used.
    Results A concise summary of the major findings of the experiment or study. Sufficient data must be provided to permit evaluation by the reviewers and public reading of the abstract. Statements such as “the data will be discussed” are not acceptable.
    Conclusions Summary of the overall findings and the importance of the study.
  • Corresponding author's contact details: E-mail address
  • Name(s) of presenting author and co-authors: First name(s) and Family name(s) (e.g. John Doe).
  • Affiliation details of all authors: Department, Institution/Hospital, City and Country. Affiliation(s) should be annotated by superscript numbers.

Tables, Graphs and Images

  • The total number of tables/graphs/images should not exceed three.
  • The maximum file size of each graph/image is 500 KB.
  • The maximum pixel size of the graph/image is 600(w) x 800(h) pixel.
  • You may upload graphs in JPG, GIF, PNG, DOC or DOCX format.

Notification of Acceptance

  • All submitted abstracts will be reviewed by the Scientific Committee according to standard review procedures.
  • Notification of acceptance will be sent by E-mail to presenting authors from January 23 (Tue), 2024.

Withdrawal of Abstracts

  • If the presenting author of an accepted abstract does not register by February 28, 2024 March 15, 2024, the abstract will be automatically withdrawn from the final program.
  • If you would like to withdraw an abstract, please notify the IMKASID 2024 secretariat (info@imkasid.kr) in writing as soon as possible.
Diamond
  • abbvie
  • CELLTRION PHARM
  • Jassen
  • SAMSUNG BIOEPIS
  • Takeda
Platinum
  • Bristrol Myers Squibb
  • DEAWOONG
  • FERRING PHARMACEUTICALS
Gold
  • Eisasi Korea Inc.
  • Pfizer
Bronze
  • GSK
  • Pharmbio Korea Inc.
  • TAEJOON

Go Top

Korean Association for the Study of Intestinal Diseases
31, Seolleung-ro 86 Gil, Gangnam-Gu, Seoul, 06193, Korea
IMKASID 2024 Secretariat [People-x, Inc.]
  • 1F, Haeoreum B/D, 16, Yeoksam-ro 17-gil, Gangnam-gu, Seoul, 06246, Korea
    [All Inquiries] info@imkasid.kr
    [Scientific Program/Abstract] +82-2-566-5951
    [Registration] +82-70-4895-6139
    [Sponsorship] +82-70-4895-6110

Copyright ⓒ Korean Association for the Study of Intestinal Diseases All rights reserved